medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 4

<< Back Next >>

Ann Hepatol 2015; 14 (4)

Prevalence in vulnerable population of liver fibrosis identified by transient elastography

Chávez-Tapia N, Torres-Sánchez J, Romero-Flores J, Álvarez-Quiroz P, Ramírez-Álvarez S, Juárez-Hernández E, Pérez-Jáuregui J, Méndez-Sánchez N, Uribe M

Language: English
References: 28
Page: 524-530
PDF size: 114.96 Kb.


ABSTRACT

Background. Transient elastography (TE) is a useful tool for the assessment of hepatic fibrosis as an alternative to liver biopsy, but it has not been validated as a screening procedure in apparently healthy people. Aim. To determine the prevalence of advanced liver fibrosis diagnosed by TE in a socioeconomically challenged rural population. Material and methods. We enrolled 299 participants aged over 18 years old from a vulnerable population in Mexico who responded to an open invitation. All participants had their history recorded and underwent a general clinical examination and a liver stiffness measurement, performed by a single operator according to international standards. Results. Overall, 7.35% participants were found to be at high risk for cirrhosis. Three variables correlated with a risk for a TE measure ≥ 9 kPa and significant fibrosis: history of alcohol intake [7.95 vs. 92.04%, odds ratio (OR) 4.47, 95% confidence interval (CI) 1.45-13.78, P = 0.0167], body mass index (BMI) ≥ 30 kg/m2 (30.87 vs. 69.12%, OR 4.25, 95%CI 1.04-6.10, P = 0.049), and history of diabetes mellitus (14.87 vs. 85.12%, OR 2.76, 95%CI 1.002-7.63, P = 0.0419). In the multivariate analyses BMI ≥ 30 kg/m2 was the only significant risk factor for advanced liver fibrosis or cirrhosis (OR 2.54, 95%CI 1.02-6.3, P = 0.0460). Conclusion. TE could be useful as a screening process to identify advanced liver fibrosis in the general and apparently healthy population.


REFERENCES

  1. Kim WR, Brown RS Jr., Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-42.

  2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.

  3. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.

  4. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-51.

  5. Hepatitis C as a public health problem in Mexico. Sal Pub Mex 2011; 53(Suppl. 1): S61-S67.

  6. Abenavoli L, Beaugrand M. Transient elastography in nonalcoholic fatty liver disease. Ann Hepatol 2012; 11: 172-8.

  7. SINAIS SNdIeS. Base de datos de defunciones generales 1979-2007. In: SUIVE SUdIplVE, editor. México 2007.

  8. INEGI. Principales causas de mortalidad por sexo en México In: Salud Sd, editor. México INEGI 2006.

  9. Lozano RS. Indicadores de Salud para el monitoreo de políticas públicas. In: Lozano R (ed.). VII Encuentro Internacional de Estadísticas de género para políticas públicas México: SEP; 2007.

  10. Cruces-Girón RG-P, ME Rangel-Jiménez, AM Sandoval-Mex, AM Tratamiento de la Insuficiencia Hepática Crónica México: Secretaría de Salud 2008.

  11. Diseases NIoDaDaK. Digestive diseases in the United States: epidemiology and impact. Bethesda, MD, 1994.

  12. Statistics NCfH. Health, United States, 2005 With Chartbook in Trends in the Health of Americans. Hyattsville, Maryland; 2005.

  13. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Eng J Med 2001; 344: 495-500.

  14. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74.

  15. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-9.

  16. Jung KS, Kim SU. Clinical applications of transient elastography. Clinical and molecular hepatology 2012; 18: 163-73.

  17. Parkes J, Guha IN, Harris S, Rosenberg WM, Roderick PJ. Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. Comparative hepatology 2012; 11: 5.

  18. Roulot D, Costes JL, Buyck JF, Warzocha U, Gambier N, Czernichow S, Le Clesiau H, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community- based population aged over 45 years. Gut 2011; 60: 977-84.

  19. Ahern J, Galea S, Hubbard A, Karpati A. Population vulnerabilities and capacities related to health: a test of a model. Social science & medicine 2008; 66: 691-703.

  20. INEGI. Censo de Población y Vivienda 2010. México; 2014.

  21. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound in medicine & biology 2003; 29: 1705-13.

  22. Juárez-Hernández E, Uribe-Ramos MH, Ramos-Ostos MH, López-Ramírez AY, Ornelas-Arroyo S, Romero-Flores JL, Méndez-Sánchez N, et al. Factors Associated with the Quality of Transient Elastography. Dig Dis Sci 2015; Mar 11. DOI 10.1007/s10620-015-3611-2.

  23. Mendez-Sanchez N, Garcia-Villegas E, Merino-Zeferino B, Ochoa-Cruz S, Villa AR, Madrigal H, Kobashi-Margain RA, et al. Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Ann Hepatol 2010; 9: 428-38.

  24. Liu B, Balkwill A, Reeves G, Beral V. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ 2010; 340: c912.

  25. Dreyer G, Hull S, Mathur R, Chesser A, Yaqoob MM. Progression of chronic kidney disease in a multi-ethnic community cohort of patients with diabetes mellitus. Diabetic medicine: a journal of the British Diabetic Association 2013.

  26. Frierson GM, Howard EN, DeFina LE, Powell-Wiley TM, Willis BL. Effect of race and socioeconomic status on cardiovascular risk factor burden: the Cooper Center Longitudinal Study. Ethnicity & disease 2013; 23: 35-42.

  27. Organization WH. Global health risks: mortality and burden of disease attributable to selected major risks, 2009.

  28. Nugent R. Chronic diseases in developing countries: health and economic burdens. Annals of the New York Academy of Sciences 2008; 1136: 70-9.




2020     |     www.medigraphic.com